• FirefoxInstall the new Firefox »
  •  Dow Down0.47% Nasdaq Down0.56%

    BioCryst Pharmaceuticals, Inc. (BCRX)

    10.06 Down 0.22(2.14%) Mar 3, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    BioCryst Pharmaceuticals, Inc.
    4505 Emperor Boulevard
    Suite 200
    Durham, NC 27703
    United States - Map
    Phone: 919-859-1302
    Fax: 919-859-1314
    Website: http://www.biocryst.com

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop drugs through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as to treat acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company’s product candidates also comprise BCX4161, a Phase II oral serine protease inhibitor for hereditary angioedema (HAE); and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses, including hemorrhagic fever viruses. Its pre-clinical products also include Two 2nd generation HAE compounds for the prevention of HAE attacks. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on BioCryst Pharmaceuticals, Inc.

    Corporate Governance 
    BioCryst Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 8. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 9; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Jon P. Stonehouse , 54
    Chief Exec. Officer, Pres and Exec. Director
    Mr. Thomas R. Staab II, CPA, 47
    Chief Financial Officer, Principal Accounting Officer, Sr. VP and Treasurer
    Ms. Alane P. Barnes , 49
    VP, Gen. Counsel and Corp. Sec.
    Dr. William P. Sheridan MBBS, 60
    Chief Medical Officer and Sr. VP
    Dr. Yarlagadda S. Babu Ph.D., 62
    Sr. VP of Drug Discovery
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders